

Product Name: Cilengitide Revision Date: 01/10/2021

Product Data Sheet

Cilengitide

Cat. No.:	A8660
CAS No.:	188968-51-6
Formula:	C27H40N8O7
M.Wt:	588.66
Synonyms:	
Target:	Angiogenesis
Pathway:	Integrin
Storage:	Store at -20°C

Solvent & Solubility

	≥29.43 mg/mL in D	DMSO; ≥22.56 mg/mL in H2O				
		Mass				
In Vitro		Solvent	1mg	5mg	10mg	
	Preparing Stock Solutions	Concentration				
	Stock Solutions	1 mM	1.6988 mL	8.4939 mL	16.9877 mL	
		5 mM	0.3398 mL	1.6988 mL	3.3975 mL	
	B the Unicourt	10 mM	0.1699 mL	0.8494 mL	1.6988 mL	
	10 m m	· · · · ·		h atech		

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Integrin inhibitor for $\alpha\nu\beta3$	Integrin inhibitor for $\alpha\nu\beta$ 3 and $\alpha\nu\beta$ 5		
IC ₅₀ & Target	2.3 nM (αvβ3), 37 nM (αv	β5)		
	Cell Viability Assay	O E Constant		
	Cell Line:	meningioma lines (Ben-Men1, IOMM-Lee, HBL-52)		
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining		
In Vitro		a higher concentration: Please warm the tube at 37 $^\circ\mathrm{C}$ for 10 minutes and/or		
		shake it in the ultrasonic bath for a while.Stock solution can be stored below		
		-20°C for several months.		
	Reacting conditions:	24 h; 100 μM/mL		
		1 www.apexbt.com		

1 | www.apexbt.com

	Applications:	Cilengitide(1, 10, and 100 $\mu\text{M/mL})$ was added to IOMM-Lee,HBL52, and
		Ben-Men1 cultures. Morphologic changes were monitored over 24 hours. In all
		three meningioma lines, cells strated to round up and detach from the flask in a
		concentration-dependent manner, showing that cilengitide decreases cell
	Blow	adhesion. Quantification of cell viability after 24 hours, cilengitide treatment
	Carlos Te ou	showed in all three cell lines a highly significant dose-dependent but rather mild
	Steeles and Parlacion.	decline of viable cells.
	Animal experiment	
	Animal models:	8- to 10-week-old Swiss Nude mice
	Dosage form:	75 mg/kg; intraperitoneal injection
	Applications:	We intended to test a daily dosage of cilengitide (75 mg/kg) as a monotherapy
		or combined with irradiation in the orthotopic mouse model. A significant
In Vivo		reduction of tongue-like brain invasion (P≤0.01) could be observed in tumors of
		mice treated with either cilengitide alone (35% decrease) or with cilengitide and
	Breddenout	irradiation (35.5% decrease).
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
		slightly differ with the theoretical value. This is caused by an experimental
		system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Wilisch-Neumann A, Kliese N, Pachow D, et al. The integrin inhibitor cilengitide affects meningioma cell motility and invasion[J]. Clinical Cancer Research, 2013, 19(19): 5402-5412.

APENBIC

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

2 | www.apexbt.com



7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com











